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More broadly, however, we need to get 
the message to the ordinary taxpayer 
and to legislators of the importance of 
basic research and of stable, long-
term funding for research that only 
governments can afford to support. 
I wonder if we could convince Fox 
News in the USA to have a ‘redneck 
scientist’ segment in which a ‘salt of 
the earth’ scientist explains to the Fox 
audience how basic research helps 
them individually.
You mentioned that music led you 
to science. Do you see any parallels 
between these two spheres? Music 
continues to be important to me. I sing 
with the Nashville Symphony Chorus, 
and the rehearsals and performances 
of the classical choral repertoire are 
a regular series of oases in my life. 
On the one hand, I am just 1 out of 
145 voices and am never recognized 
individually. On the other hand, it is 
a privilege and pleasure for me to 
have the opportunity to be a part of a 
program with professional musicians 
(they are totally out of my league). My 
choral participation is a metaphor for 
the way I view my ultimate contribution 
to science. There are few scientists 
who achieve name recognition status, 
and almost all of those who do reach 
that stature during their research-active 
years are practically forgotten within 
a few years after their retirement. For 
example, I have been shocked that the 
work and contributions of my graduate 
supervisor (Pittendrigh) — a dominant 
figure of chronobiology who died 17 
years ago — are rarely discussed 
nowadays. Therefore, lasting personal 
recognition is not a realistic motivation 
for becoming a researcher/teacher. 
However, we contribute to a process 
that is larger than ourselves. In that 
sense, we are each a ‘voice in the 
chorus’. While I was initially attracted 
to science by the fallacy that I might 
be recognized as having accomplished 
great things, now my goals are more 
realistic: firstly, in my teaching, I can 
influence the lives and decisions of 
hundreds of students every year in 
ways that will be largely unknowable to 
me and, secondly, in my research, I can 
enjoy an endeavor that remains fresh 
and challenging as new experimental 
results force us to continuously re-
evaluate previous conclusions.
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What is precision genome 
engineering? Exactly that! You know 
what a genome is; ‘engineering’ 
means that we want to change that 
DNA, and ‘precision’ means we want 
to do it in a very specific, targeted 
way.
Sounds challenging, why would you 
want to do that? Lots of reasons. For 
example, we might want to make a 
mutation in a gene in an experimental 
organism in order to see what the 
effect was and thus get an insight 
into the gene’s function. With real 
precision, we could introduce an 
exact mutation that corresponds to a 
human genetic disease allele into an 
experimental organism. That would 
allow us to examine the physiological 
consequences of that mutation in 
more detail than we could just by 
looking at people.
Are there some more practical, 
real-world applications? You bet! 
People are using precision genome 
engineering with crop plants and 
food animals to give them improved 
characteristics. Think about maize 
that was more drought resistant, or 
canola that produced more beneficial 
oil. How about pigs with more muscle 
mass — call that pork — or dairy cows 
with no horns to bother their sisters 
or the farmer. These modifications are 
already under way.
How can you get these changes 
to be made efficiently and with 
real specificity? The key is to use 
proteins that will cut DNA — called 
nucleases — and to direct them to 
exactly the place in the genome 
that you want to modify. The first 
engineered proteins of this kind were 
called zinc-finger nucleases, or ZFNs. 
They have a nuclease attached to 
zinc finger modules that come from 
natural DNA binding proteins (mainly 
transcription factors) and know how 
to find and bind to very specific DNA 
sequences. There are natural and 
synthetic fingers that in the right 
Quick guide combination can recognize quite a range of DNA sequences. About four 
years ago, another type of DNA-
binding module was characterized 
that has a very simple way of 
recognizing DNA — one module 
for each base pair. The nucleases 
made from these are called TALENs 
(transcription activator-like effector 
nucleases), and they have stolen 
quite a bit of territory from ZFNs.
So these proteins make a cut in the 
DNA strand, but what happens then? 
Once a break is made at a specific 
site by the nuclease, the cell’s double 
strand repair machinery hurries to fix 
it and sometimes makes a mistake. 
This introduces a mutation right at 
the break site, and often knocks out 
the function of a gene. Another type 
of repair uses a DNA template to 
copy information across the break. 
If we put into cells a template that 
carries sequence changes we want to 
introduce, they will often get copied 
in. That’s how you would put in a 
human disease mutation, for example. 
Together ZFNs and TALENs have 
been used successfully to modify 
the genomes of about 30 different 
species, including humans.
Humans? You’re messing with 
my genome? No (not yet, but stay 
vigilant). Lots of genome engineering 
has been done in cultured human 
cells, partly to make disease models, 
partly just to work out the technology. 
Ultimately we want to use these 
nucleases for beneficial gene therapy. 
Right now there are clinical trials 
going on with ZFNs targeted to the 
human CCR5 gene. The product of 
this gene is a protein that the human 
immunodeficiency virus (HIV) needs 
in order to infect T cells. It turns 
out we can get along without this 
protein — there are natural CCR5 
mutants. The therapy is to take 
T cells from HIV-infected people, 
treat them in the lab to knock out 
CCR5, then put them back into the 
same person. This will prevent the 
development of AIDS by providing 
a population of HIV-resistant T 
cells, and there won’t be a rejection 
problem because the cells came from 
the same person who receives them.
Sounds amazing, but what can you 
do besides help AIDS patients? The 
things that look easiest right now are 
ones where the nuclease treatment 
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Have you ever stumbled across Ernst 
Haeckel’s stunning 19th century 
art prints representing complex 
symmetrical forms that look like 
snowflakes, armored knights, or even 
futuristic space stations? Or maybe 
walking down an indo-pacific beach, 
you have taken a closer look at the 
warm sand only to realize that the 
‘sand’ is really countless, minute 
earthly stars? Chances are you did 
not realize it, but in both cases you 
were looking at the skeletons of 
single-celled organisms belonging 
to Rhizaria, a large group, or 
‘supergroup’, of eukaryotes. Various 
kinds of rhizarians have long been 
known to biologists, as evidenced 
by the fame and frequency with 
which Haeckel’s illustrations have 
been reproduced, but the idea that 
these organisms are all related to one 
another emerged only recently. And 
this means that Rhizaria, as a whole, 
is one of the most poorly understood 
supergroups of eukaryotes. 
That Rhizaria lags far behind 
more studied groups is of course a 
challenging statement to prove, but 
a fair approximation to illustrate the 
depth of our knowledge, or rather the 
lack of it, is to look at the available 
genetic and genomic information. 
Figure 1 depicts our current 
understanding of the evolutionary 
tree of eukaryotes, as assembled 
by more than 20 years of molecular 
phylogenetics and advanced 
microscopy. In addition to positioning 
Rhizaria among its ‘peers’, this figure 
also shows how researchers have 
allocated the genomic resources 
across the whole phylogenetic 
spectrum of eukaryotes. In this tree, the 
thickness of each branch corresponds 
to the number of complete nuclear 
genomes available from members of 
those lineages collectively. Looking 
at the last common ancestor of 
eukaryotes (here at the center, or the 
unresolved base of the tree), one can 
see that we have sequenced a lot of 
nuclear genomes, but as we move out 
to the tips it becomes apparent that 
most sequencing effort has focused on 
a few lineages only, primarily animals, 
Primer fungi, plants, and their respective parasites. Microbial eukaryotic 
lineages (aka the protists) are generally 
undersampled, but with only one 
complete genome available, that of the 
chlorarachniophyte Bigelowiella natans 
and the foraminifer Reticulomyxa 
filosa, the entire supergroup Rhizaria 
still stands out among protists in the 
extreme paucity of genomic data. It is 
not surprising that large, multicellular 
organisms are better studied, as these 
have always been the main subjects 
of biological research. By extension, 
parasites of animals and plants have 
also attracted much attention, and 
among protists the vast majority 
of sequenced genomes are from 
pathogens of humans or economically 
important animal and plant species. 
For example, the apicomplexan 
parasites, such as the malaria agent 
Plasmodium falciparum, top the 
list of protist groups with complete 
genomes (currently about 30). Another, 
slightly weaker bias comes from our 
preference for sequencing genomes 
from photosynthetic species, for 
instance green and red algae with 
11 and 5 genomes, respectively, or 
diatoms with 4 genomes (Figure 1). 
So why is Rhizaria so understudied? 
One reason is that they almost entirely 
run contrary to the above noted 
biases. For a start, only two relatively 
small subgroups are photosynthetic, 
one being the chlorarachniophytes, 
which not surprisingly include one of 
the two rhizarian genomes currently 
available (B. natans). Moreover, 
no rhizarian parasite of human is 
currently known, and only a handful 
parasitize commercially relevant 
species, mostly crops or invertebrates 
(see below). Aside from these biases, 
Rhizaria also faces a problem of 
a more technical nature: they are 
hard to cultivate, and until recently 
a relatively large scale cell culture 
was a prerequisite for launching 
major sequencing projects in order 
to meet the material (DNA or RNA) 
requirements.
So does that mean that rhizarian 
genomics, and by extension rhizarian 
research as a whole, faces a dark 
future, being labeled ‘difficult and not 
sufficiently sexy’? On the contrary, our 
awareness of the global significance 
of Rhizaria is on the rise, just as 
the technical difficulties are rapidly 
receding. Rhizaria itself represents a 
fascinating reservoir of unexplored 
diversity. At the environmental and can be done outside the body 
— ex vivo, as we say. Any condition 
involving blood cells would be a 
candidate: thalassemia (hemoglobin 
deficiencies), severe combined 
immune deficiencies (SCID), and 
others. When it comes to delivering 
the nucleases to intact organs, the 
challenge becomes greater, but 
people are working on it. Researchers 
are also using these nucleases to 
modify human stem cells in culture. 
As we learn enough about such cells 
to have some confidence in putting 
them into the body, we will also have 
the tools to correct genetic defects in 
them. You can imagine manipulating 
neural stem cells in culture to help 
reverse neurodegenerative diseases 
that have a genetic cause.
What’s next? There is a lot of work 
ahead to bring the applications I’ve 
hinted at to fruition. But beyond the 
slogging, there is a new nuclease 
technology, with the catchy name of 
CRISPR. This system uses a single 
bacterial protein to do the DNA 
cutting, and it is guided to its target 
by an RNA molecule using Watson-
Crick base pairing. In that way, it 
is simpler than ZFNs and TALENs, 
and it threatens to take over entirely. 
The CRISPR approach has already 
been used in a number of systems 
very effectively, but there are some 
concerns about whether it will be 
specific enough for use in people. 
Keep your eyes open. The future will 
also be full of surprises.
Where can I find out more?
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